secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001193125-25-232562
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences raises $135M in PIPE; unveils BAFF-R candidate JADE201
-----------------------------------------------------------------------

- Private placement raises ~$135M gross via 13.37M shares at $9.14 and pre-funded warrants; close expected Oct 8, 2025.
- Pro forma shares outstanding ~67.4M; cash runway extended into first half 2028.
- Licenses BAFF-R antibodies from Paragon Therapeutics; up to $22M in milestones plus low-to-mid-single-digit royalties.
- JADE201 is a half-life extended afucosylated anti-BAFF-R mAb; Phase 1 in rheumatoid arthritis expected H1 2026.
- NHP data shows ~2-fold half-life increase vs ianalumab and sustained B-cell depletion after single SC dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525232562/0001193125-25-232562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525232562/d58004d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-232562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer